Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.

You may also be interested in...



AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.

AstraZeneca Puts Academics’ Triple Reuptake Inhibitor On Fast Track

Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.

DOV Out-Licenses Pain Candidate Bicifadine To XTL

XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063651

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel